Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy

Study examined the risk of reactivation of hepatitis B virus in B-cell lymphoma patients who receive treatment with rituximab or obinutuzumab.